Title: Beraprost
CAS Registry Number: 88430-50-6
CAS Name: 2,3,3a,8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-5-butanoic acid
Additional Names: dl-16-methyl-18,19-tetradehydro-5,6,7-trinor-4,8-inter-m-phenyleneprostaglandin I2; dl-4-[(1R,2R,3aS,8bS)-1,2,3a,8b-tetrahydro-2-hydroxy-[(3S,4RS)-3-hydroxy-4-methyl-oct-6-yne-(E)-1-enyl]-5-cyclopenta(b)benzofuranyl]butanoic acid; befaprost
Manufacturers' Codes: ML-1229
Molecular Formula: C24H30O5
Molecular Weight: 398.49
Percent Composition: C 72.34%, H 7.59%, O 20.08%
Literature References: Platelet aggregation inhibitor; stable analog of prostacyclin, q.v. Prepn: K. Ohno et al., EP 84856; eidem, US 4474802 (1983, 1984 both to Toray); eidem, Adv. Prostaglandin Thromboxane Leukotriene Res. 15, 279 (1985). PGI2 receptor binding: N. Kajikawa et al., Arzneim.-Forsch. 39, 495 (1989). Series of articles on pharmacology: ibid. 856-876. Clinical pharmacokinetics: J.-L. Demolis et al., J. Cardiovasc. Pharmacol. 22, 711 (1993). Clinical trial in intermittent claudication: M. Lievre et al., ibid. 27, 788 (1996); in diabetic angiopathy: Y. Okuda et al., Prostaglandins 52, 375 (1996).
Derivative Type: Sodium salt
CAS Registry Number: 88475-69-8
Manufacturers' Codes: ML-1129; TRK-100
Trademarks: Dorner (Toray); Procylin (Kaken)
Molecular Formula: C24H29NaO5
Molecular Weight: 420.47
Percent Composition: C 68.56%, H 6.95%, Na 5.47%, O 19.03%
Therap-Cat: Antithrombotic; vasodilator (peripheral).
Keywords: Prostaglandin/Prostaglandin Analog; Vasodilator (Peripheral); Antithrombotic.
Berbamine Berberine Berberis Aristata Berbine Bergapten

Systematic (IUPAC) name
5-butanoic acid
Clinical data
AHFS/ International Drug Names
Legal status  ?
Routes Oral
Pharmacokinetic data
Bioavailability 50–70%
Metabolism Unknown
Half-life 35–40 minutes
Excretion  ?
CAS number 88430-50-6 88475-69-8
ATC code B01AC19
PubChem CID 5282428
IUPHAR ligand 1967
ChemSpider 5293169 YesY
Chemical data
Formula C24H30O5 
Mol. mass 398.492 g/mol
 YesY (what is this?)  (verify)

Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.